The practitioner has the option to submit to the special access program for Cystagon. It is still approved today. It was never not approved. But a practitioner has to present a request that explains the medical rationale for why the available therapy is not right for that patient.
There are currently in the order of about 64 patients receiving Cystagon through the special access program.